Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01758367 | Decitabine Followed by Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloblastic Leukemia(AML) After Allogeneic Stem Cell Transplantation | unknown | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Aug 31, 2016 | clinicaltrials |
| NCT02881749 | Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis Fungoides | unknown | Phase 2 | 68 | Thomas Jefferson UniversityOTHER | 0 | Aug 30, 2016 |
| clinicaltrials |
| NCT02883036 | Vitro Study of Tigecycline to Treat Chronic Myeloid Leukemia | unknown | — | 100 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Aug 30, 2016 | clinicaltrials |
| NCT01602939 | Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis | unknown | Phase 2 / Phase 3 | 10 | Hospital Virgen de la SaludOTHER | 1 | Aug 29, 2016 | clinicaltrials |
| NCT02878278 | Differences Between Chidamide Taken Daily and Twice a Week in Therapeutic Effect,Pharmacokinetics, Pharmacodynamics and EB Virus Activation | unknown | Phase 2 | 24 | Huiqiang HuangOTHER | 0 | Aug 25, 2016 | clinicaltrials |
| NCT02856685 | A Study of Mitoxantrone Hydrochloride Liposome Infusion | unknown | Phase 1 / Phase 2 | 60 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Aug 22, 2016 | clinicaltrials |
| NCT02859948 | A Study of SKLB1028 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia | unknown | Phase 1 | 18 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Aug 9, 2016 | clinicaltrials |
| NCT02860598 | Observatory of the Prescription of Erythropoietin as Treatment of Anemia Induced by Chemotherapy or Allograft Conditioning Among the Patients With a Haematological Malignancy(EPREX/LAM-ALLO) | unknown | — | 104 | Hospices Civils de LyonOTHER | 1 | Aug 9, 2016 | clinicaltrials |
| NCT02856997 | Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell Lymphoma | unknown | Phase 2 | 35 | Yuankai ShiOTHER | 0 | Aug 5, 2016 | clinicaltrials |
| NCT02456350 | Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies | unknown | Phase 1 | 36 | Shenzhen Second People's HospitalOTHER | 1 | Aug 3, 2016 | clinicaltrials |
| NCT02457650 | T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies | unknown | Phase 1 | 36 | Shenzhen Second People's HospitalOTHER | 1 | Aug 3, 2016 | clinicaltrials |
| NCT02544724 | NM-IL-12 (rHuIL-12) In Relapsed/Refractory Diffuse Large B- Cell Lymphoma (DLBCL) Undergoing Salvage Chemotherapy | unknown | Phase 2 | 12 | Neumedicines Inc.INDUSTRY | 0 | Aug 3, 2016 | clinicaltrials |
| NCT02766868 | Sequential Intensive Chemotherapy Followed by RIC for Refractory and Relapse ALL | unknown | Phase 2 | 20 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Aug 1, 2016 | clinicaltrials |
| NCT02851589 | Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Aug 1, 2016 | clinicaltrials |
| NCT02848183 | Optimal Treatment Strategy Based on for Pediatric AML | unknown | Phase 2 | 350 | Samsung Medical CenterOTHER | 1 | Jul 28, 2016 | clinicaltrials |
| NCT01146262 | Vaccination by Leukemic Apoptotic Corpse Autologous Pulsed Dendritic Cells for Acute Myelogenous Leukemia (AML) Patients in First or Second Complete Remission (CR)(CD laM)(CD lam) | unknown | Phase 1 / Phase 2 | 5 | Nantes University HospitalOTHER | 1 | Jul 26, 2016 | clinicaltrials |
| NCT01279902 | Abbreviated R-CHOP in Completely Excised Stage I or II DLBCL | unknown | Phase 2 | 32 | Asan Medical CenterOTHER | 1 | Jul 26, 2016 | clinicaltrials |
| NCT02184897 | Pharmacokinetic and Pharmacodynamic Study of Lenograstim for Hematopoietic Stem Cell Mobilization | unknown | N/A | 24 | Asan Medical CenterOTHER | 1 | Jul 26, 2016 | clinicaltrials |
| NCT02404571 | GDP in Frontline Chemotherapy for Patients With PTCL-NOS | unknown | Phase 2 | 28 | Chinese Academy of Medical SciencesOTHER | 1 | Jul 26, 2016 | clinicaltrials |
| NCT02842931 | R-Dose-adjusted (DA) - EPOCH-21 Versus R-modified Non-Hodgkin Lymphoma (NHL)-Berlin-Frankfurt-Munster (BFM)-90 Program (mNHL-BFM-90) and Autologous Stem Cells Transplantation (Auto-SCT) in DLBCL With Poor Prognosis | unknown | Phase 3 | 300 | National Research Center for Hematology, RussiaNETWORK | 1 | Jul 25, 2016 | clinicaltrials |
| NCT02836639 | BEB Conditioning Regimen for Autologous Stem-cell Transplantation(ASCT) in Non-Hodgkin's Lymphoma | unknown | Phase 2 | 20 | Pusan National University HospitalOTHER | 1 | Jul 19, 2016 | clinicaltrials |
| NCT01484171 | HLA-mismatched Microtransplantation for High Risk Acute Myeloid Leukemia | unknown | Phase 3 | 50 | The Affiliated Hospital of the Chinese Academy of Military Medical SciencesOTHER | 1 | Jul 13, 2016 | clinicaltrials |
| NCT02171117 | Safety and Efficacy Study of Microtransplantation to Treat Elderly Acute Myeloid Leukemia(IMCG-EAML) | unknown | Phase 3 | 196 | The Affiliated Hospital of the Chinese Academy of Military Medical SciencesOTHER | 1 | Jul 13, 2016 | clinicaltrials |
| NCT02828774 | Peptide-drug-conjugates for Personalized, Targeted Therapy of Chronic Lymphocytic Leukemia | unknown | — | 30 | Assuta Medical CenterOTHER | 0 | Jul 12, 2016 | clinicaltrials |
| NCT02619071 | ChEmo-Genomics Based Treatment of Acute Myeloid Leukemia(CeGAL) | unknown | N/A | 87 | Institut Paoli-CalmettesOTHER | 1 | Jun 28, 2016 | clinicaltrials |
| NCT02813837 | Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies | unknown | N/A | 30 | Innovative Cellular Therapeutics Co., Ltd.OTHER | 1 | Jun 28, 2016 | clinicaltrials |
| NCT01671826 | Autologous Stem Cell Transplantation for Myeloma Patients Over 65 Years(LATMM) | unknown | — | 55 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jun 24, 2016 | clinicaltrials |
| NCT02315118 | Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies | unknown | Phase 1 / Phase 2 | 18 | National University Hospital, SingaporeOTHER | 1 | Jun 22, 2016 | clinicaltrials |
| NCT02779101 | Study on Pembrolizumab for Recurrent Primary Central Nervous System Lymphoma (PCNSL) | unknown | Phase 2 | 21 | Prof. Dr. Matthias PreusserOTHER | 1 | Jun 22, 2016 | clinicaltrials |
| NCT02809274 | Incidence of Iron Deficiency in Polycythemia Vera (PV) and Association With Disease Features | unknown | — | 200 | Rambam Health Care CampusOTHER | 1 | Jun 22, 2016 | clinicaltrials |
| NCT02808520 | Social Inequalities in the Participation and Activity in Children and Adolescents With Hodgkin-lymphoma | unknown | — | 700 | Martin-Luther-Universität Halle-WittenbergOTHER | 0 | Jun 21, 2016 | clinicaltrials |
| NCT02803840 | Low-dose Radiotherapy for Diffuse Large B-cell Lymphoma | unknown | Phase 2 | 25 | Centro di Riferimento Oncologico - AvianoOTHER | 1 | Jun 17, 2016 | clinicaltrials |
| NCT01991158 | GAD-M Regimen As First-Line Treatment in Untreated Extranodal NK/T Cell Lymphoma | unknown | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Jun 14, 2016 | clinicaltrials |
| NCT02797041 | Bortezomib as First Salvage Therapy for Myeloma Patients Previously Exposed to Bortezomib as Initial Treatment.(REBOUND) | unknown | — | 100 | IRCCS Centro di Riferimento Oncologico della BasilicataOTHER | 0 | Jun 14, 2016 | clinicaltrials |
| NCT02792491 | Phase II Prospective Trial of Addition of Rituximab to Reduced Dose CHOP Chemotherapy in DLBC L Patients Aged 65 Years and Over | unknown | Phase 2 | 57 | Pusan National University HospitalOTHER | 0 | Jun 9, 2016 | clinicaltrials |
| NCT02777736 | CNS Prophylaxis in Diffuse Large B-cell Lymphoma(CLSG-CNS-001) | unknown | Phase 3 | 500 | Czech Lymphoma Study GroupOTHER | 1 | Jun 6, 2016 | clinicaltrials |
| NCT02791217 | Identification of Hematological Malignancies and Therapy Predication Using microRNAs as a Diagnostic Tool | unknown | — | 100 | Assuta Medical CenterOTHER | 0 | Jun 6, 2016 | clinicaltrials |
| NCT01522872 | Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 98 | Threshold PharmaceuticalsINDUSTRY | 1 | Jun 2, 2016 | clinicaltrials |
| NCT02784561 | Study of Busulfan and FLAG Conditioning Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation | unknown | Phase 4 | 80 | Chinese PLA General HospitalOTHER | 0 | May 27, 2016 | clinicaltrials |
| NCT01933711 | Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and Mantle Cell Lymphoma | unknown | Phase 3 | 328 | University Hospital HeidelbergOTHER | 1 | May 13, 2016 | clinicaltrials |
| NCT02757586 | Treatment of Chronic Lymphocytic Leukemia | unknown | — | 70 | Peking University People's HospitalOTHER | 0 | May 13, 2016 | clinicaltrials |
| NCT01690065 | Nilotinib-Chemotherapy in CML Myeloid BP or Bcr-abl(+) AML(NICE-BORA) | unknown | Phase 2 | 46 | Ulsan University HospitalOTHER | 1 | May 11, 2016 | clinicaltrials |
| NCT02422719 | Radotinib as 3rd or Later Line Therapy in CP-CML(REVITAL) | unknown | Phase 2 | 73 | Ulsan University HospitalOTHER | 1 | May 11, 2016 | clinicaltrials |
| NCT01501708 | Caspofungin Based Combined Anti-fungal Therapy for Proven or Probable Invasive Fungal Infection | unknown | Phase 2 | 55 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | May 10, 2016 | clinicaltrials |
| NCT02765620 | PERCIST Criteria for Response Evaluation With Solid Tumors | unknown | — | 150 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 6, 2016 | clinicaltrials |
| NCT02758925 | CyBeR Association in Relapsed/Refractory DLBCL(CyBeR-Lymph) | unknown | Phase 2 | 78 | University Hospital, CaenOTHER | 0 | May 4, 2016 | clinicaltrials |
| NCT02759822 | Haploidentical Hematopoietic Stem Cell Transplantation for Acute Leukemias | unknown | — | 30 | Leonardo Javier ArcuriOTHER_GOV | 1 | May 3, 2016 | clinicaltrials |
| NCT02757040 | Combination of Ibrutinib and As2O3 in the Treatment of CLL | unknown | Phase 3 | 70 | Peking University People's HospitalOTHER | 0 | Apr 29, 2016 | clinicaltrials |
| NCT02753062 | Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell Lymphoma(PTLD) | unknown | Phase 2 | 22 | Asan Medical CenterOTHER | 1 | Apr 27, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Aug 31, 2016source: clinicaltrials